Starting Treatment with Agonist Replacement Therapies (START) Walter Ling, Ph.D. Lead Investigator Director, Integrated Substance Abuse Programs, UCLA 11075 Santa Monica Boulevard Suite 225 Los Angeles, CA 90025 lwalter@ix.netcom.com

START is a randomized, open-label, multi-center phase IV study designed to compare the changes in liver enzymes related to treatment with Buprenorphine/Naloxone (BUP/NX) to the changes in liver enzymes related to treatment with methadone in an outpatient setting. Secondary objectives will be to attempt to identify risk factors at baseline and during treatment that could contribute to interactions with BUP/NX or methadone causing liver dysfunction, and to assess abstinence from illicit drugs or alcohol during the active study period.

This CTN "platform" study was requested by the FDA and uses the collaboration of two NIDA divisions -- the Center for Clinical Trials Network (CCTN) and the Division of Pharmacotherapies & Medical Consequences of Drug Abuse.

  RELATED STUDIES

• CTN-0027a: START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies

	Find publications in the Library about Protocol CTN-0027